BioSpaceExelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine TumorsYesterdayMore
OncLiveCHMP Recommends EU Approval of Cabozantinib for Pancreatic and Extra-Pancreatic Neuroendocrine TumorsYesterdayMore
GlobeNewswireIpsen receives positive CHMP opinion for Cabometyx® in previously treated advanced neuroendocrine tumorsYesterdayMore
Full CoverageFull Coverage